Univ. of Montreal Pursues Interleukin IL-22 to Battle Liver Disease

Oct 30, 2018 | IL-22, Liver Disease, Liver Health

Researchers from the University of Montreal Hospital Research Center, Liver Immunology Research Unit have discovered how a protein called interleukin 22 (IL-22) accelerates fibrosis during episodes of chronic hepatitis by amplifying the signal of the fibrogenic cytokine TGF-β. The fibrogenic nature of IL-22 had been unknown up to now.  The new finding allows us to understand its interaction when cominged with TGF-β, a cytokine that is produced during liver inflammation.  Indeed cases of advanced fibrosis confirm the pathogenic aspect of IL-22.  See the research at http://immunology.sciencemag.org/content/3/28/eaar7754

Lead Research/Investigator

Naglaa Shoukry, Ph. D


Pin It on Pinterest